These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 30576445)

  • 1. Vulnerability of frontal brain neurons for the toxicity of expanded ataxin-3.
    Schmidt J; Mayer AK; Bakula D; Freude J; Weber JJ; Weiss A; Riess O; Schmidt T
    Hum Mol Genet; 2019 May; 28(9):1463-1473. PubMed ID: 30576445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3.
    Schmidt J; Schmidt T; Golla M; Lehmann L; Weber JJ; Hübener-Schmid J; Riess O
    J Neurochem; 2016 Jul; 138(1):150-62. PubMed ID: 26990650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyglutamine-induced neurodegeneration in SCA3 is not mitigated by non-expanded ataxin-3: conclusions from double-transgenic mouse models.
    Hübener J; Riess O
    Neurobiol Dis; 2010 Apr; 38(1):116-24. PubMed ID: 20079840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD.
    Switonski PM; Szlachcic WJ; Krzyzosiak WJ; Figiel M
    Neurobiol Dis; 2015 Jan; 73():174-88. PubMed ID: 25301414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversibility of symptoms in a conditional mouse model of spinocerebellar ataxia type 3.
    Boy J; Schmidt T; Wolburg H; Mack A; Nuber S; Böttcher M; Schmitt I; Holzmann C; Zimmermann F; Servadio A; Riess O
    Hum Mol Genet; 2009 Nov; 18(22):4282-95. PubMed ID: 19666958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence.
    Bichelmeier U; Schmidt T; Hübener J; Boy J; Rüttiger L; Häbig K; Poths S; Bonin M; Knipper M; Schmidt WJ; Wilbertz J; Wolburg H; Laccone F; Riess O
    J Neurosci; 2007 Jul; 27(28):7418-28. PubMed ID: 17626202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes.
    Ramani B; Panwar B; Moore LR; Wang B; Huang R; Guan Y; Paulson HL
    Hum Mol Genet; 2017 Sep; 26(17):3362-3374. PubMed ID: 28854700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyglutamine-expanded ataxin-3 causes cerebellar dysfunction of SCA3 transgenic mice by inducing transcriptional dysregulation.
    Chou AH; Yeh TH; Ouyang P; Chen YL; Chen SY; Wang HL
    Neurobiol Dis; 2008 Jul; 31(1):89-101. PubMed ID: 18502140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3).
    Hübener J; Weber JJ; Richter C; Honold L; Weiss A; Murad F; Breuer P; Wüllner U; Bellstedt P; Paquet-Durand F; Takano J; Saido TC; Riess O; Nguyen HP
    Hum Mol Genet; 2013 Feb; 22(3):508-18. PubMed ID: 23100324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel SCA3 Knock-in Mouse Model Mimics the Human SCA3 Disease Phenotype Including Neuropathological, Behavioral, and Transcriptional Abnormalities Especially in Oligodendrocytes.
    Haas E; Incebacak RD; Hentrich T; Huridou C; Schmidt T; Casadei N; Maringer Y; Bahl C; Zimmermann F; Mills JD; Aronica E; Riess O; Schulze-Hentrich JM; Hübener-Schmid J
    Mol Neurobiol; 2022 Jan; 59(1):495-522. PubMed ID: 34716557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T1-11 and JMF1907 ameliorate polyglutamine-expanded ataxin-3-induced neurodegeneration, transcriptional dysregulation and ataxic symptom in the SCA3 transgenic mouse.
    Chou AH; Chen YL; Chiu CC; Yuan SJ; Weng YH; Yeh TH; Lin YL; Fang JM; Wang HL
    Neuropharmacology; 2015 Dec; 99():308-17. PubMed ID: 26254860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional profiling and biomarker identification reveal tissue specific effects of expanded ataxin-3 in a spinocerebellar ataxia type 3 mouse model.
    Toonen LJA; Overzier M; Evers MM; Leon LG; van der Zeeuw SAJ; Mei H; Kielbasa SM; Goeman JJ; Hettne KM; Magnusson OT; Poirel M; Seyer A; 't Hoen PAC; van Roon-Mom WMC
    Mol Neurodegener; 2018 Jun; 13(1):31. PubMed ID: 29929540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyglutamine-expanded ataxin-3 impairs long-term depression in Purkinje neurons of SCA3 transgenic mouse by inhibiting HAT and impairing histone acetylation.
    Chou AH; Chen YL; Hu SH; Chang YM; Wang HL
    Brain Res; 2014 Oct; 1583():220-9. PubMed ID: 25139423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of the polyglutamine protein ataxin-3 with Rad23 regulates toxicity in Drosophila models of Spinocerebellar Ataxia Type 3.
    Sutton JR; Blount JR; Libohova K; Tsou WL; Joshi GS; Paulson HL; Costa MDC; Scaglione KM; Todi SV
    Hum Mol Genet; 2017 Apr; 26(8):1419-1431. PubMed ID: 28158474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory genes are upregulated in expanded ataxin-3-expressing cell lines and spinocerebellar ataxia type 3 brains.
    Evert BO; Vogt IR; Kindermann C; Ozimek L; de Vos RA; Brunt ER; Schmitt I; Klockgether T; Wüllner U
    J Neurosci; 2001 Aug; 21(15):5389-96. PubMed ID: 11466410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward therapeutic targets for SCA3: Insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance.
    Li X; Liu H; Fischhaber PL; Tang TS
    Prog Neurobiol; 2015 Sep; 132():34-58. PubMed ID: 26123252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Karyopherin α-3 is a key protein in the pathogenesis of spinocerebellar ataxia type 3 controlling the nuclear localization of ataxin-3.
    Sowa AS; Martin E; Martins IM; Schmidt J; Depping R; Weber JJ; Rother F; Hartmann E; Bader M; Riess O; Tricoire H; Schmidt T
    Proc Natl Acad Sci U S A; 2018 Mar; 115(11):E2624-E2633. PubMed ID: 29476013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological enhancement of retinoid-related orphan receptor α function mitigates spinocerebellar ataxia type 3 pathology.
    Watanave M; Hoshino C; Konno A; Fukuzaki Y; Matsuzaki Y; Ishitani T; Hirai H
    Neurobiol Dis; 2019 Jan; 121():263-273. PubMed ID: 30343032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spinocerebellar ataxia type 3 (SCA3): thalamic neurodegeneration occurs independently from thalamic ataxin-3 immunopositive neuronal intranuclear inclusions.
    Rüb U; de Vos RA; Brunt ER; Sebestény T; Schöls L; Auburger G; Bohl J; Ghebremedhin E; Gierga K; Seidel K; den Dunnen W; Heinsen H; Paulson H; Deller T
    Brain Pathol; 2006 Jul; 16(3):218-27. PubMed ID: 16911479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant Ataxin-3-Containing Aggregates (MATAGGs) in Spinocerebellar Ataxia Type 3: Dynamics of the Disorder.
    Raj K; Akundi RS
    Mol Neurobiol; 2021 Jul; 58(7):3095-3118. PubMed ID: 33629274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.